CCRM
Cynthia Lavoie, PhD, MBA, is currently serving as the Managing Director of AllosteRx Capital Management (Canada) Inc. since 2018. Cynthia is also the President and Chief Investment Officer at CCRM Enterprises Inc. Cynthia has extensive experience in the life sciences and venture capital industry, having held positions at companies like Profound Medical Inc. and Fibrocor Therapeutics. Additionally, Cynthia has a background in research, with a Ph.D in Molecular & Cellular Biology from McGill University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.